

ARIPIPRAZOLE LAUROXIL: INTEGRATING MEDICINAL CHEMISTRY AND PHARMACEUTICS FOR SCHIZOPHRENIA TREATMENT

Rajesh Kumar¹, Reema Garg², Subhi Sharma³

School of Pharmacy, Desh Bhagat University, Mandi Gobindgarh, Punjab, India

ABSTRACT

Schizophrenia and bipolar disorder are chronic mental illnesses that impose a significant burden of disability and socioeconomic disadvantage worldwide. For many individuals, long-term illness management is often compromised by poor adherence to antipsychotic medications, which leads to increased relapse rates, worsening symptoms, and repeat hospitalizations. Long-Acting Injectables (LAIs) are designed to improve this problem by offering prolonged drug delivery over longer times, convenience of treatment compliance, and to maintain levels of compliance overall. LAIs have many advantages over oral therapy, which include: stable plasma levels of drug, less frequent dosing, and improved monitoring of patient compliance. This review highlights the importance of LAIs in psychiatric care as well as their role in improving treatment outcomes for bipolar disorder and schizophrenia. This review highlights the clinical effects of schizophrenia and bipolar disorder, describes the shortcomings of oral antipsychotic treatment, and reviews the therapeutic benefits of long-acting injectables (LAIs). Specific emphasis will be placed on the structure–activity relationship (SAR) and formulation approach of aripiprazole lauroxil, demonstrating the convergence of prodrug design and pharmaceutical advancement in addressing persistent challenges in mental health treatment.

LIST OF ABBREVIATIONS

LAIs- Long-Acting Injectables, SAR- Structure Activity Relationship, AL- Aripiprazole Lauroxil, AM- Aripiprazole monohydrate

1. INTRODUCTION

Schizophrenia and bipolar disorder are chronic, episodic mental disorders that can place a considerable burden on patients, family, and care givers, and global healthcare systems. Typically beginning in early adulthood, these disorders are characterised by an episodic or persistent disturbance of mood, perception, and cognition, which impede occupational and social functioning[1, 2]. According to the World Health Organisation, schizophrenia affects approximately 20 million people globally, while bipolar illness affects 40 - 50 million people, with both being classified as significant contributors to years lived with disability within mental health. A major barrier to the successful long-term management of these illnesses is poor adherence to oral antipsychotic medications. Poor adherence can arise for a variety of reasons, including lack of insight, cognitive impairment, stigma associated with psychiatric illnesses, and adverse reactions to drugs. Poor adherence leads to serious problems, including higher rates of relapse, unintended emergency department presentations, involuntary psychiatric rehospitalizations, and functional decline, which can erode treatment progress and impair quality of life[3, 4].

To reduce these barriers, LAI antipsychotics emerged as a

credible treatment option. By providing extended drug exposure through intramuscular injection at fixed intervals (e.g., every 2 - 8 weeks), LAIs eliminate the work of daily dosing and may improve adherence by facilitating the more immediate identification of medication absences, as well as potentially improve aspects like therapeutic levels of consistent plasma drug levels, reduced peak-trough variability, and perhaps fewer side effects relative to oral formulations[5, 6].

Among the newest long-acting injectables for this indication, Aripiprazole Lauroxil is noteworthy because of its prodrug formulation, longer dose intervals, and favorable pharmacology. The long-acting formulation of the atypical antipsychotic aripiprazole represents an exciting advance in drug delivery and schizophrenia burden management. Long-acting formulations usually derive from complex SAR research and pharmacologic progress that includes nano- or microcrystallization suspension technologies, which enhance prolonged release of medications[7-9].

2. MECHANISM OF ARIPIPRAZOLE

Aripiprazole is a second generation (atypical) antipsychotic with a unique mechanism of action. While first generation antipsychotics work primarily as dopamine receptor antagonists, aripiprazole acts as a partial agonist at dopamine

D2 receptors and achieves stability of dopaminergic activity. This partial agonist function serves to decrease excess dopamine activity in active pathways; for example, dopamine activity in the mesolimbic tract, which is largely responsible for the positive symptoms of schizophrenia[9, 10]. In turn, aripiprazole would be able to preserve and possibly even increase dopamine activity in hypoactive areas such as the mesocortical pathway, where cognitive and negative symptoms of schizophrenia are primarily encountered.

Additionally, aripiprazole has partial agonist activity at serotonin 5-HT_{1A} receptors; these actions likely accentuate any anxiolytic or antidepressant benefits, while attenuating serotonergic activity at 5-HT_{2A} receptors, which reduces the potential for extrapyramidal side effects, thus improving more general tolerability for people taking the medication. Aripiprazole has been medically approved for schizophrenia, bipolar I disorder, major depressive disorder (as an adjunct), irritability associated with autistic spectrum disorder, and Tourette's disorder. Its relatively unique receptor occupancy profile and long plasma half-life (75 hours) decrease the risk of sedation, weight gain, metabolic dysfunction, and extrapyramidal symptoms, making it suitable for chronic courses of treatment in many psychiatric populations[11]. However, notwithstanding the benefits, oral aripiprazole requires administration on a daily basis, which would create challenges in certain psychiatric patients due to poor adherence, often driven by cognitive impairment, insight into their illness, as well as stigma and submaximal fortitude in taking a prescription except when absolutely necessary[12].

To address these limitations, long-acting injectable (LAI) forms of aripiprazole have been developed. Long-acting injectables can have substantial advantages by maintaining steady therapeutic plasma concentrations over long periods of time (typically 4-8 weeks) and therefore can reduce the risk of relapse and hospitalisation. Long-acting injectables can also ensure better oversight of treatment adherence and simplify scheduling for drug treatment for patients and carers[13, 14]. The development of long-acting formulations of aripiprazole, including aripiprazole lauroxil, represents a major step forward in psychiatric pharmacotherapy by combining pharmacodynamic benefits at the receptor level with enhanced delivery and adherence methods, making it an




Figure : Structure of aripiprazole lauroxil

excellent option for the maintenance treatment of schizophrenia and bipolar disorder.

3. STRUCTURE ACTIVITY RELATIONSHIP

Structure Activity Relationship refers to the connection between a drug or chemical compound's molecular structure and its pharmacological or biological effects. Structure-activity relationships studies determine discrete molecular features that are essential for biological action, called pharmacophores. This knowledge provides a rational basis for drug design, particularly where structural alterations are applied to improve important pharmacological properties such as potency, selectivity, bioavailability, and safety. SAR significantly reduces the trial-and-error of drug discovery and development by helping chemists to optimize molecular features and as such, helps to quickly identify potential safe and effective medicines.

Core: Quinolinone derivative with a piperazine ring attached by a butoxy side chain.

The compound has three major pharmacophoric elements:

- Aryl-piperazine moiety (important for binding affinity to D₂/5-HT_{1A}/5-HT_{2A} receptors)
- Butoxy linker (affects receptor binding kinetics and flexibility)
- Quinolinone structure (important for partial agonist activity)

Table : Highlights of SAR

S.No.	Features of Structure	Role of SAR
1.	Quinoline ring	Crucial for partial agonism; alterations in this area might convert the medication into a complete antagonist or diminish its potency.
2.	Aryl-piperazine group	Essential for partial agonism; changes in location can either change the drug from a partial agonist to a complete antagonist or decrease potency
3.	Butoxy linker	Effects distance and orientation of pharmacophores; if shortened activity decreased.

Aripiprazole lauroxil is a prodrug, wherein the hydroxyl group of aripiprazole is esterified with a lauroyl (C12) chain via a linker. This change:

- Increases lipophilicity, promoting depot formation in muscle tissue,
- Delays conversion to active aripiprazole, allowing prolonged release over weeks,
- Is cleaved enzymatically in the body after intramuscular injection to slow release of active drug.




Figure 2 : SAR of the Drug

The lauroxil ester side chain is critical to the structure-activity relationship (SAR) of aripiprazole lauroxil. This lipophilic moiety enhances solubility, allowing it to be used in injectable depot formulations. The ester chain prevents systemic distribution so that the compound needs to be metabolically hydrolyzed into the active moiety of aripiprazole. This prodrug design allows for prolonged release of the drug, resulting in long-duration therapeutic effect and potentially

improved adherence [15, 16].

- Lipophilicity:** Enhanced by lauroxil chain for depot formation.
- Depot formation:** A significant characteristic of lauroxil is the facilitation of intramuscular depot formation for long-term release of drug.
- The rate of hydrolysis is controlled enzymatically** to allow for progressive bioconversion to active aripiprazole.

4. PHARMACEUTICAL DESIGN OF LAI FORMULATIONS

a) Principles of Design for Long-Acting Injectable (LAI) Systems

Long-acting injectable (LAI) systems are designed to have a long duration of drug release, which leads to greater patient adherence and therapeutic plasma levels of a drug over an extended period of time. Key design principles are:

- i) **Depot Formation:** The formulation must create a depot for the drug at the injection site (typically intramuscular or subcutaneously) from which the drug will be absorbed over time.
- ii) **Prodrugs or Poorly Soluble drug:** Common within long-acting injectables (LAIs) are lipophilic prodrugs such as aripiprazole lauroxil, and poorly water soluble drug particles to attenuate the absorption.
- iii) **Controlled Particle size:** The size of the drug particles (micro, nanoscale) can be modified to provide a reliable and even release of medication.
- iv) **Stabilising Excipients and Vehicles:** The formulation must consist of safe, biocompatible ingredients (e.g., polymers and suspending agents) to enhance stability and allow injection.

b) Nano/Microcrystal Suspension Formulation Techniques

Aripiprazole lauroxil (AL) is produced as a micronised crystalline suspension. There are many formulation advantages:

- i) Microcrystal technology provides a large surface area for prodrugs to undergo their slow degradation.

- ii) Particle engineering allows one to control the release rate and overall duration of effect.
- iii) Stabilisers prevent agglomeration and sedimentation of the particles, providing steady dosing.
- iv) The suspension is formulated in a viscous, biocompatible solution for ease of injection and depot stability for efficacy.

At the time of manufacture, Aripiprazole Lauroxil is formulated with a proprietary aqueous suspension system of biocompatible polymers and surfactants, enabling the suspension medium to stabilise drug crystals and provide uniformity[17-19]. We specifically selected micron-compressed particles, not nanoparticles, to create dissolution and hydrolysis limitations. Larger, substantial particle size allows for sustained drug release, permitting depot formation.

After intramuscular injection, aripiprazole lauroxil creates a depot in the muscle tissue, which gradually dissipates into the surrounding interstitial tissues with time. This is followed by a bioconversion process that begins with enzymatic hydrolysis of aripiprazole lauroxil into N-hydroxymethyl aripiprazole and then further continues to active aripiprazole. The multi-step conversion process accounts for delayed therapeutic onset[20]. After conversion, active medication is distributed regularly into the bloodstream and maintains plasma concentrations, with therapeutic levels maintained for approximately 4 to 8 weeks, depending on the dose offered and individual patient metabolism, thus providing the ability to have long-term effectiveness with fewer doses.

Table 2 :Parameters of Aripiprazole

S.no	Parameter	Aripiprazole Lauroxil	Aripiprazole monohydrate
1	Chemical Form	Lauroxil ester of Aripiprazole	Active aripiprazole
2	Activation	Enzymatic hydrolysis required	The active drug is directly released
3	Onset of action	Slower onset	The onset of action is fast
4	Injection site	Deltoid or gluteal	Intramuscular
5	Dosing interval	4,6, and 8 weeks	Monthly
6	Plasma Stability	After the initial delay sustained level is required	More immediate release kinetics

The prodrug nature and microcrystalline formulation of aripiprazole lauroxil allow it to provide much more prolonged therapeutic benefits, but it also creates the need for oral supplementation (oral overlap) during initiation to compensate for the delayed onset.

5. PHARMACOKINETICS AND DOSING STRATEGY

Aripiprazole lauroxil is designed as a long-acting injection

(LAI) to provide long-lasting clinical efficacy through a well-controlled PK mechanism. After an intravenous injection, medication will not immediately enter the bloodstream. Once in the muscle tissue, medication will remain to use as a depot, which will ultimately release medication over time[21]. Unlike the dispersible formulation, aripiprazole lauroxil is a prodrug that must be converted in the body for

activation upon administration. There are two enzymatic phases of the conversion that occurs: first, it is converted to an intermediate (N-hydroxymethyl aripiprazole), and finally, hydrolyzed into the active drug, aripiprazole[22]. This two-phased approach does lead to a lagging onset of action, with peak blood levels of medication typically occurring approximately 41 days post-injection. To address this delay, patients are instructed to take immediate-release aripiprazole tablets for the first 21 days after their initial injection, which will ensure consistent coverage in their first 21 days after the injection[23].

A main advantage of aripiprazole lauroxil is its adaptable dose regimen, which may be customised to meet individual requirements. Patients may receive injections every 4, 6, or 8 weeks, contingent upon the chosen dosage, which varies from 441 mg to 1064 mg. This prolonged dose interval markedly diminishes the necessity for frequent clinic visits and may enhance adherence, particularly in patients who find daily drug regimens challenging. This adaptability renders it a convenient and pragmatic choice for the long-term management of schizophrenia and other chronic psychiatric disorders[24, 25].

Aripiprazole lauroxil has many important differences compared to other long-acting injectable antipsychotics, particularly with risperidone, paliperidone palmitate, or olanzapine pamoate. Importantly, it has a much lower risk of side effects associated with EPS and high prolactin levels, often associated with dopamine antagonist medications like risperidone. There will still be side effects when taking risperidone, paliperidone palmitate, or olanzapine pamoate as well. Other injectables may use a biweekly or monthly route of administration as opposed to a long acting delivery of every 6-week or 8-week dosing every 6 or 8 weeks[26]. There will need to be initial oral overlap to adjust to dosing, along with delay to dosing; however, many patients and clinicians believe the benefits of continuous plasma concentrations, reduced chances of relapse in their treatment, and better long-term tolerability outweigh the drawbacks. The various unique pharmacokinetic properties and flexible dose schedule makes this an important tool in enhancing long-term outcomes in psychiatry treatment[27].

6. CLINICAL OUTCOMES AND ADVANTAGES

Aripiprazole lauroxil offers several meaningful advantages in the long-term treatment of schizophrenia, especially for individuals who face challenges with daily medication routines. As a long-acting injectable (LAI), it provides a simpler and more reliable option for staying on track with

treatment[28].

Key Advantages:

- a) **Improved medication adherence:** Since it's given as an injection every 4, 6, or 8 weeks, there's no need to remember a daily pill-this is especially helpful for patients who struggle with consistent oral medication.
- b) **Reduced relapse and hospitalization rates:** With more consistent blood levels of the medication, patients are less likely to experience a relapse or end up in the hospital due to missed doses.
- c) **Better tolerability:** Compared to many other LAIs, aripiprazole lauroxil tends to cause fewer side effects like movement disorders (extrapyramidal symptoms) or hormone disturbances (like elevated prolactin).
- d) **Greater patient acceptance:** Infrequent injections are often seen as less burdensome, making it easier for patients to commit to long-term treatment.
- e) **Discreet and convenient:** For many, the ability to receive treatment once every few weeks in a clinical setting is more private and manageable than taking daily medication in public or remembering complex schedules.

There are still limitations that need to be considered, even with the benefits. Because aripiprazole lauroxil is a prodrug, there is no immediate effect of the drug. It takes time for the metabolite to get into the system and metabolized to an active form. Patients require an initial course of oral aripiprazole for the first 21 days after their first injection to ensure efficacy until the injectable formulation takes effect[29-31]. In addition, even if generally well-tolerated, some patients may have mild responses at the injection site, such as soreness, edema, or redness.

Still, for many patients, the trade-off is worth it. The decreased frequency of dosing, in addition to managing symptoms, and decreasing emergency room visits and relapses makes aripiprazole lauroxil a strong option for patients trying to recover and maintain some form of stability from schizophrenia[31, 32].

7. FUTURE PERSPECTIVES AND INNOVATIONS

As mental health care continues to progress, the treatment landscape for long-acting injectable (LAI) antipsychotics is undergoing exciting changes. Researchers are now developing new-generation LAIs designed to make life easier for patients. These advanced formulations are being engineered to last even longer some with the goal of stretching dosing intervals to as long as three months or more[33]. For patients, this could mean fewer clinic visits, less disruption to daily life, and improved chances of staying

on treatment.

At the same time, innovation in drug delivery technology is opening up new possibilities. Scientists are exploring the use of biodegradable implants and in-situ forming depots, which can be placed just under the skin or in muscle tissue[34]. These systems gradually release medication over time, potentially removing the need for repeat injections altogether. Some of these delivery methods are even being designed to adjust release based on the body's signals or be fine-tuned remotely, paving the way for therapies that adapt to individual needs in real time.

Alongside these advancements, there's growing momentum toward personalizing treatment plans. Tools like pharmacogenetic testing, which examines how a patient's genes affect drug response, therapeutic drug monitoring, and even digital adherence tracking could help clinicians customize every aspect of LAI therapy[35]. From how often a dose is given to what type of formulation is used, these developments move us closer to truly patient-centered psychiatric care. In many ways, aripiprazole lauroxil is already a step in this direction. Its flexible dosing options, delayed-release formulation, and favorable tolerability profile have shown how well-designed prodrug and depot technologies can benefit patients. It sets the stage for future therapies that are not only effective but also align with the needs and lifestyles of those they're meant to support.

8. CONCLUSION

The emergence of aripiprazole lauroxil highlights the very important relationship between a drug's structural scaffold and its chemical pharmacology. The lauroxil ester is more than just a minor modification for curiosity's sake; instead, it is critical to the activity of the medication as a long-acting injectable (LAI). This SAR allows the drug to remain dormant within the body until it undergoes regulated enzymatic conversion into its active form, thereby sustaining the release of the drug over time. Researchers have purposefully designed the molecular scaffold to satisfy the requirements of depot delivery systems to effectively create a drug delivery system that enables longer dosing intervals, stable plasma concentrations, and improved patient adherence. Clinically, the use of prodrug approaches in LAI formulations is clinically relevant and provides a distinct advantage, particularly in the evolution of managing chronic psychiatric disorders like schizophrenia. Prodrugs such as aripiprazole lauroxil allow a delay (and prolonged) therapeutic effect, which is essential to mitigate the risk of relapse, sustain a

continuous treatment regimen, and to optimize the likelihood of recovery. In real-world practice, where medication non-adherence is among the most common causes of relapse and hospitalization, such advances represent important progress. The LAI prodrug approach bridges chemistry and clinical need, and not only improves pharmacokinetics, but it can also improve relevant patient-oriented outcomes, which in the context of modern psychiatry, is essential.

REFERENCES

1. McCutcheon, R.A., T.R. Marques, and O.D. Howes, Schizophrenia-an overview. *JAMA psychiatry*, 2020. 77(2): p. 201-210.
2. Schultz, S.H., S.W. North, and C.G. Shields, Schizophrenia: a review. *American family physician*, 2007. 75(12): p. 1821-1829.
3. Insel, T.R., Rethinking schizophrenia. *Nature*, 2010. 468(7321): p. 187-193.
4. Weinberger, D.R. and P. Harrison, Schizophrenia. 2011: John Wiley & Sons.
5. Correll, C.U., et al., Pharmacokinetic characteristics of long-acting injectable antipsychotics for schizophrenia: an overview. *CNS drugs*, 2021. 35(1): p. 39-59.
6. Brissos, S., et al., The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. *Therapeutic advances in psychopharmacology*, 2014. 4(5): p. 198-219.
7. Park, E.J., et al., Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia. *Archives of pharmacological research*, 2013. 36(6): p. 651-659.
8. Stevens, G.L., G. Dawson, and J. Zummo, Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia. *Early intervention in psychiatry*, 2016. 10(5): p. 365-377.
9. Fusar-Poli, P., M.J. Kempton, and R.A. Rosenheck, Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials. *International clinical psychopharmacology*, 2013. 28(2): p. 57-66.
10. Roth, T.L., et al., Epigenetic mechanisms in schizophrenia. *Biochimica et Biophysica Acta (BBA)-General Subjects*, 2009. 1790(9): p. 869-877.
11. Lang, U.E., et al., Molecular mechanisms of schizophrenia. *Cellular Physiology and Biochemistry*, 2007. 20(6): p. 687-702.
12. Bishara, D. and D. Taylor, Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. *Drugs*, 2008. 68(16): p. 2269-2292.
13. Meyer-Lindenberg, A., From maps to mechanisms through neuroimaging of schizophrenia. *Nature*, 2010. 468(7321): p. 194-202.
14. Lieberman, J.A., Pathophysiologic mechanisms in the

- pathogenesis and clinical course of schizophrenia. *Journal of Clinical Psychiatry*, 1999. 60(12):p. 9-12.
15. Ali, M., C. Kartal, and S. Sar, Aripiprazole-induced tremor: a case report. *Klinik Psikofarmakoloji Bulteni*, 2019. 29: p. 153-153.
16. Kumar, A., et al., Aripiprazole: An FDA approved bioactive compound to treat schizophrenia-A mini review. *Current Drug Discovery Technologies*, 2020. 17(1): p. 23-29.
17. Mali, S. and N. Oza, Central composite design for formulation and optimization of long-acting injectable (LAI) microspheres of Paliperidone Palmitate. *Int. J. Appl. Pharm*, 2021. 13(5): p. 87-98.
18. Bauer, A., et al., Current state and opportunities with long-acting injectables: industry perspectives from the innovation and quality consortium "long-acting injectables" working group. *Pharmaceutical research*, 2023. 40(7): p. 1601-1631.
19. Gomeni, R. and F. Bressolle-Gomeni, Convolution-based approach for modeling the paliperidone extended release and Long-Acting Injectable (LAI) PK of once-, and three-monthly products administration and for optimizing the development of new LAI products. *Journal of Pharmacokinetics and Pharmacodynamics*, 2023. 50(2): p. 89-96.
20. Rapinesi, C., et al., Long-acting injectable (LAI) aripiprazole formulations in the Treatment of schizophrenia and bipolar disorder: A systematic review. *Clinical Drug Investigation*, 2019. 39(8): p. 713-735.
21. Thummel, K.E., et al., Design and optimization of dosage regimens: pharmacokinetic data. *Goodman & Gilman's the pharmacological basis of therapeutics*, 2006. 11: p. 1787-1888.
22. Hard, M.L., et al., Pharmacokinetic profile of a 2-month dose regimen of aripiprazole lauroxil: a phase I study and a population pharmacokinetic model. *CNS drugs*, 2017. 31(7): p. 617-624.
23. Weiden, P.J., et al., Pharmacokinetics, safety, and tolerability of a 2-month dose interval regimen of the long-acting injectable antipsychotic aripiprazole lauroxil: results from a 44-week phase I study. *CNS drugs*, 2020. 34(9): p. 961-972.
24. Sommi, R.W., et al., Aripiprazole lauroxil dosing regimens: understanding dosage strengths and injection intervals. *CNS spectrums*, 2022. 27(3): p. 262-267.
25. Citrome, L., Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil. *Expert review of clinical pharmacology*, 2016. 9(2): p. 169-186.
26. Citrome, L., et al., Aripiprazole Lauroxil: Development and Evidence-Based Review of a Long-Acting Injectable Atypical Antipsychotic for the Treatment of Schizophrenia. *Neuropsychiatric Disease and Treatment*, 2025: p. 575-596.
27. Meyer, J.M., Aripiprazole lauroxil nanocrystal suspension. *Curr. Psychiatry*, 2018. 17: p. 34.
28. Maini, K., et al., Aripiprazole Lauroxil, a novel injectable long-acting antipsychotic treatment for adults with schizophrenia: a comprehensive review. *Neurology international*, 2021. 13(3): p. 279-296.
29. McEvoy, J.P., et al., Long-term effect of aripiprazole lauroxil on health-related quality of life in patients with schizophrenia. *BMC psychiatry*, 2021. 21(1): p. 164.
30. Nasrallah, H.A., et al., Aripiprazole lauroxil 2-month formulation with 1-day initiation in patients hospitalized for an acute exacerbation of schizophrenia: exploratory efficacy and patient-reported outcomes in the randomized controlled ALPINE study. *BMC psychiatry*, 2021. 21(1): p. 492.
31. Citrome, L., et al., Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia. *International Clinical Psychopharmacology*, 2016. 31(2): p. 69-75.
32. Lauriello, J., et al., Real-world outcomes and costs following 6 months of treatment with the long-acting injectable (LAI) aripiprazole lauroxil for the treatment of schizophrenia. *CNS drugs*, 2021. 35(10): p. 1123-1135.
33. Kotzalidis, G.D., et al., Aripiprazole IM depot as an option for the treatment of bipolar disorder. *Expert Opin Pharmacother*, 2021. 22(11): p. 1407-1416.
34. Cameron, C., et al., Aripiprazole Lauroxil Compared with Paliperidone Palmitate in Patients with Schizophrenia: An Indirect Treatment Comparison. *Value Health*, 2017. 20(7): p. 876-885.
35. Sun, Y., et al., LC-MS/MS method for the determination of the prodrug aripiprazole lauroxil and its three metabolites in plasma and its application to in vitro biotransformation and animal pharmacokinetic studies. *J Chromatogr B Analyt Technol Biomed Life Sci*, 2018. 1081-1082: p. 67-75.